Starting Testosterone Therapy: 200 mg Monthly is NOT Reasonable
For a 50-year-old man with a total testosterone of 175 ng/dL, starting with 200 mg testosterone cypionate or enanthate monthly is NOT a reasonable regimen—this dosing interval is too long and will result in excessive peak-trough fluctuations that compromise symptom control and safety monitoring.
Recommended Starting Regimen
The Endocrine Society guidelines 122 and AACE guidelines 33 provide clear dosing recommendations for injectable testosterone:
Start with one of these evidence-based regimens:
- 75-100 mg intramuscularly weekly (preferred for stable levels)
- 150-200 mg intramuscularly every 2 weeks (acceptable alternative)
The 200 mg monthly regimen you're considering falls outside guideline-recommended intervals and creates problematic pharmacokinetic patterns.
Why Monthly Dosing Fails
Monthly administration of short-acting testosterone esters (cypionate/enanthate) produces:
- Supraphysiologic peaks in the first week (>700 ng/dL), increasing risk of erythrocytosis, acne, mood changes, and estradiol-related symptoms 45
- Subtherapeutic troughs in weeks 3-4 (<400 ng/dL), causing return of hypogonadal symptoms 11
- Difficult laboratory interpretation—timing of blood draw relative to injection becomes critical and results misleading 4
Recent comparative data 5 demonstrates that 100 mg weekly produces significantly lower rates of hematocrit elevation above 54% compared to 200 mg every 2 weeks (1% vs 8%, p=0.023), despite similar total testosterone increases. Monthly dosing would amplify these risks further.
Proper Initiation Protocol
Before Starting Treatment
Confirm the patient meets diagnostic criteria 12:
- Symptoms of androgen deficiency (sexual dysfunction, fatigue, reduced muscle mass)
- Two separate morning total testosterone measurements <300 ng/dL (some guidelines use <350 ng/dL)
- Rule out secondary causes (medications, obesity, sleep apnea)
Baseline Safety Assessment 113
Absolute contraindications:
- Prostate or breast cancer
- Hematocrit >50%
- PSA >3 ng/mL without urologic evaluation (for men ≥40 years)
Relative contraindications requiring optimization first:
- Untreated obstructive sleep apnea
- Severe BPH (IPSS >19)
- Uncontrolled heart failure
Required baseline labs:
- Hematocrit
- PSA and digital rectal exam (age 40+)
- Consider: lipids, glucose, liver function
Starting Dose Selection
For this 50-year-old patient with testosterone 175 ng/dL:
Option 1 (Recommended): 100 mg IM weekly 22
- Provides most stable testosterone levels
- Minimizes peak-related adverse effects
- Easier laboratory monitoring (can check anytime)
- Lower erythrocytosis risk 5
Option 2 (Acceptable): 150-200 mg IM every 2 weeks 323
- More convenient for some patients
- Still within guideline recommendations
- Requires midpoint monitoring (day 7)
- Higher peak-trough variation than weekly
The FDA label 6 states "50 to 400 mg should be administered every two to four weeks," but this broad range reflects historical practice rather than optimal dosing. Modern guidelines have refined this based on pharmacokinetic data.
Monitoring Strategy
At 3-6 Months 1111
Assess clinical response:
- Improvement in sexual function, energy, mood
- If no symptom improvement, consider discontinuation 7
Laboratory monitoring:
- Testosterone level: Measure midway between injections for every-2-week dosing, or anytime for weekly dosing
- Hematocrit: Stop therapy if >54% until it decreases; evaluate for hypoxia/sleep apnea; restart at reduced dose 11
- PSA: Check in men ≥40 years
Ongoing Monitoring 12
- Annual follow-up visits
- Annual hematocrit and PSA (age ≥40)
- Urologic referral if:
- PSA increase >1.4 ng/mL in any 12-month period
- PSA velocity >0.4 ng/mL/year (after 6 months on therapy)
- Abnormal digital rectal exam
Common Pitfalls to Avoid
- Using monthly dosing intervals—creates unacceptable peak-trough variation with short-acting esters
- Checking testosterone at wrong time—must be midpoint for every-2-week dosing; results otherwise uninterpretable 4
- Starting therapy without confirming diagnosis—requires symptoms PLUS two low morning testosterone measurements 12
- Ignoring hematocrit monitoring—older men have greater erythrocytosis risk 11
- Continuing therapy without symptom improvement—reassess at 12 months and discontinue if ineffective 7
Alternative Formulations
If injection frequency is a concern, consider 22:
- Testosterone gel (5-10 g daily)—more stable levels but higher cost, transference risk
- Testosterone undecanoate IM (750 mg every 10 weeks after loading)—longer-acting but restricted access in US
- Transdermal patches (2-6 mg/24h)—stable levels but skin irritation common
However, intramuscular testosterone cypionate/enanthate remains the most cost-effective option with similar efficacy 7.
Bottom Line for This Patient
Start with 100 mg testosterone cypionate or enanthate intramuscularly weekly, not 200 mg monthly. This provides stable testosterone levels in the mid-normal range, minimizes adverse effects, simplifies monitoring, and aligns with current guideline recommendations 122. Reassess at 3-6 months with symptom evaluation, testosterone level (can check anytime with weekly dosing), hematocrit, and PSA. Adjust dose based on achieving mid-normal testosterone (450-600 ng/dL) with symptom improvement and acceptable safety parameters.